News

Leadartis announces the publication «An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad anti-tumor activity in humanized murine cancer models without toxicity” in Clinical Cancer Research

https://clincancerres.aacrjournals.org/ Although systemic administration of anti-4-1BB-agonistic IgGs, have shown promise in early clinical studies have not completed clinical development due to their severe hepatotoxicity. Here  we demonstrate that a humanized EGFR-specific 4-1BB-agonistic trimerbody exhibits potent anti-tumor activity […]

Leadartis reaches a major milestone with the demonstration of absence of toxicity of its drug candidate in preclinical models

Leadartis reaches a major milestone with the demonstration of absence of toxicity of its EGFR-targeted 4-1BB-agonistic bispecific Trimerbody which does not Induce Hepatotoxicity in transgenic mice with liver expression of human EGFR (https://www.frontiersin.org/articles/10.3389/fimmu.2020.614363/full). These data support the […]

Load More
  • 1
  • 2
  • 6

Start typing and press Enter to search